Charles River Laboratories Intl. Inc vs Datadog Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $300.35 (market cap $14.23B), while Datadog Inc trades at $280.26 (market cap $98.31B). The key difference: Datadog Inc is far larger — about 6.9× Charles River Laboratories Intl. Inc's market cap, and Datadog Inc is more actively traded (2,936,660 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Datadog Inc for 76 Days on average.
| CRL | DDOG | |
|---|---|---|
Market Cap | $14.23B | $98.31B |
Volume | 1,176,885 | 2,936,660 |
Sector | Health | Technology |
52-Week High | $310.77 | $288.15 |
52-Week Low | $149.93 | $102.62 |
Typical Hold Time | 33 Days | 76 Days |
Enterprise Value | $17.06B | $94.61B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.53, up 0.08% on the day, with a bullish technical outlook and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, though it faces profitability challenges with a negative net income margin and ROE. Recent investor day presentations highlighted a strategic plan targeting 5-7% revenue growth and $300 million in savings by 2030, driving positive sentiment.
The outlook is cautiously optimistic, supported by analyst buy ratings and a $305.50 consensus price target, but risks include ongoing margin pressure, volatile non-human primate costs, and a high valuation multiple. Earnings growth and successful execution of the new strategic plan are critical for sustained upside.
Datadog (DDOG) trades at $271.34, down 2.48% on the day, but maintains a bullish technical outlook with strong support near $269. The company continues to deliver robust revenue growth, reaching $3.43B in 2025, and has beaten earnings estimates for three consecutive quarters. Analyst sentiment remains overwhelmingly positive with a consensus price target of $276.10, though high valuation multiples like a P/E of 547.6 signal premium pricing. Recent news highlights accelerating AI and enterprise customer expansion as key growth drivers.
The outlook for DDOG is favorable given its consistent earnings beats and strategic positioning in cloud observability and AI infrastructure. However, investors face risks from elevated valuations, negative net cash flow, and competitive pressures in the cloud software sector. The stock's proximity to its consensus target suggests limited near-term upside, making execution on growth initiatives critical for further appreciation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →